Clinical Trial

A Multicenter Study to Optimize Microembolic Signal Classification Based on Double--Blind Multiparametric Assessment by Human Experts Using an Universal Graphical Interface [MESOMEGA]

Study acronym: MESOMEGA
Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated December 10, 2025 (before its estimated December 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
Microembolic signals (MES) is a powerful predictor of future embolic events. This study aims to develop and validate a accurate model of classification of MES obtained by transcranial Doppler. monitoring of However, MES detection is technically demanding and requires expert interpretation. By providing a reproducible framework for MES interpretation, this work aims to facilitate MES integration into future clinical trials and decision-making.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-10.
Trial Details
NCT Number NCT07172165
Lead Sponsor Universidade do Porto
Collaborators: Sound Vascular Neurology, RISE-Heatlh, CRU-RISE, University of Ostrava, Maastricht University Medical Center, Justus-Liebig University Gießen Medical Center, University of Bern, Centro Hospitalar De São João, E.P.E., Houston Methodist DeBakey Heart & Vascular Center
Conditions Microemboli, Stroke, Transcranial Doppler Ultrasound
Enrollment 850 participants
Start Date 2025-05-15
Primary Completion 2025-12-15 (estimated)
Study Completion 2026-03-15 (estimated)
Updated on ClinicalTrials.gov 2025-12-10